{"entity":{"id":"nct06453902","kind":"trial","name":"TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients","aka":[],"tldr":"A phase 2 trial of TGRX-678 in chronic myeloid leukaemia, run by Shenzhen TargetRx Co., Ltd., now recruiting.","summary":"TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients is a phase 2 interventional study registered as NCT06453902 by Shenzhen TargetRx Co., Ltd., with 40 participants planned, started 2024-07-15 and due to reach its primary completion in 2026-06-30. Interventions recorded: TGRX-678.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06453902","url":"https://clinicaltrials.gov/study/NCT06453902"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["shenzhen-targetrx"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06453902","phase":"2","setting":"A Single-arm, Open-label, Multi-center Phase II Study Evaluating Efficacy and Safety of TGRX-678 in CML-AP Patients Relapsed or Refractory From 3rd-generation TKI Treatment","sponsor":"Shenzhen TargetRx Co., Ltd.","enrolled":40,"outcomes":[]},"route":"/trials/nct06453902/","neighbours":{"cancer":[{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"}],"company":[{"id":"shenzhen-targetrx","kind":"company","name":"Shenzhen TargetRx","route":"/companies/shenzhen-targetrx/"}]}}